Metagenomi Therapeutics (MGX) Receivables - Accured (2023 - 2026)

Metagenomi Therapeutics (MGX) has 4 years of Receivables - Accured data on file, last reported at $1.0 million in Q1 2026.

• Receivables - Accured for Q1 2026 came in at $1.0 million, down 37.5% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.0 million (down 37.5% YoY), and the FY2025 annual result was $1.2 million, down 25.0% from the prior year.
• Receivables - Accured eased to $1.0 million in Q1 2026 per MGX's latest filing, from $1.2 million in the prior quarter.
• Over five years, Receivables - Accured peaked at $1.6 million in Q3 2024 and troughed at $1.0 million in Q4 2023.
• A 4-year average of $1.3 million and a median of $1.3 million in 2024 frame the typical range for Receivables - Accured.
• The sharpest annual moves came in 2024 and 2026: Receivables - Accured jumped 60.0% in 2024, then slumped 37.5% in 2026.
• A 4-year view of Receivables - Accured shows it stood at $1.0 million in 2023, then surged by 60.0% to $1.6 million in 2024, then fell by 25.0% to $1.2 million in 2025, then declined by 16.67% to $1.0 million in 2026.
• Business Quant data shows MGX's Receivables - Accured at $1.0 million in Q1 2026, $1.2 million in Q4 2025, and $1.3 million in Q3 2025.